Driehaus Capital Management’s Travere Therapeutics TVTX Stock Holding History

Driehaus Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.8M	Buy	1,439,134 +156,616	+12%	+$6.94M	0.47%	66
2026 Q1	$38.1M	Buy	1,282,518 +381,114	+42%	+$11.4M	0.28%	124
2025 Q4	$34.4M	Buy	901,404 +193,944	+27%	+$6.31M	0.23%	140
2025 Q3	$16.9M	Buy	+707,460	New	+$13.3M	0.12%	222
2025 Q2	–	Sell	-2,767,693	Closed	-$49.6M	–	505
2025 Q1	$49.6M	Buy	2,767,693 +549,718	+25%	+$11.2M	0.48%	61
2024 Q4	$38.6M	Buy	2,217,975 +1,904,733	+608%	+$33.7M	0.32%	103
2024 Q3	$4.38M	Buy	+313,242	New	+$3.26M	0.04%	285
2015 Q3	–	Sell	-13,449	Closed	-$446K	–	616
2015 Q2	$446K	Buy	+13,449	New	+$368K	0.02%	472

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Driehaus Capital Management's TVTX Position: Q2 2026 in Review

Driehaus Capital Management increased its Travere Therapeutics (TVTX) stake by 12% in Q2 2026, buying an estimated $6.94M and bringing the position to 1,439,134 shares worth $81.8M. The position accounts for 0.47% of the portfolio, ranked #66.

Driehaus Capital Management first reported a position in TVTX in Q2 2015 and has held it in 8 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Driehaus Capital Management held 1,439,134 shares of Travere Therapeutics worth $81.8M as of Q2 2026.
Driehaus Capital Management bought 156,616 Travere Therapeutics shares in Q2 2026, an estimated $6.94M.
Travere Therapeutics made up 0.47% of Driehaus Capital Management's portfolio in Q2 2026, its #66 holding.
Driehaus Capital Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 8 quarters since.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.